Johnson & Johnson is to buy oncology specialist Cougar Biotechnology for $1 billion in cash to boost its pipeline of late-stage cancer therapeutics.
The move will allow J&J to expand into cancer targets where it is currently absent, such as prostate cancer. Cougar's...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

